x min read

Active Watch List: Galena Biopharma, Inc. (NASDAQ:GALE), Northwest Biotherapeutics, Inc. (NASDAQ:NWBO), Cardiome Pharma Corp. (NASDAQ:CRME), CRA International Inc. (NASDAQ:CRAI), Aaron's, Inc. (NYSE:AAN)

Active Watch List: Galena Biopharma, Inc. (NASDAQ:GALE), Northwest Biotherapeutics, Inc. (NASDAQ:NWBO), Cardiome Pharma Corp. (NASDAQ:CRME), CRA International Inc. (NASDAQ:CRAI), Aaron's, Inc. (NYSE:AAN)
Written by
Charles Donlon
Published on
November 14, 2014
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook

Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced the dosing of the first patient in a new NeuVax™ (nelipepimut-S) Phase 2 clinical trial to prevent breast cancer recurrence in high risk HER2 3+ and/or HER2 gene-amplified breast cancer patients in combination with Herceptin® (trastuzumab; Genentech/Roche). The patients will be defined as 3+ by immunohistochemistry (IHC) or are HER2 2+ and/or fluorescence in situ hybridization (FISH) >2.0, also described as gene-amplified. Galena Biopharma, Inc. (NASDAQ:GALE) belongs to Healthcare sector. Its weekly performance is -7.84%. On last trading day company shares ended up $1.88. Galena Biopharma, Inc. (NASDAQ:GALE) distance from 50-day simple moving average (SMA50) is -7.50%. Levi & Korsinsky, LLP is investigating Northwest Biotherapeutics, Inc. ("Northwest Bio" or the "Company") (NASDAQ:NWBO) in connection with possible breaches of federal securities laws. The investigation regards concerns that the Company made misleading statements regarding its clinical trial for DC-Vax Direct, its experimental cancer vaccine. Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) shares increased 0.68% in last trading session and ended the day at $5.92. NWBO return on assets is -867.60%. Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) quarterly performance is -10.44%. Cardiome Pharma Corp (NASDAQ:CRME) posted its quarterly earnings results on Friday. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.13. During the same quarter in the previous year, the company posted ($0.29) earnings per share. On 13 November, Cardiome Pharma Corp. (NASDAQ:CRME) shares increased 0.47% and was closed at $8.53. CRME EPS growth in last 5 year was 15.80%. Cardiome Pharma Corp. (NASDAQ:CRME) year to date (YTD) performance is 36.92%. CRA International, Inc. (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that an auction process will be conducted for FirstEnergy Corp.’s (NYSE: FE) Pennsylvania utilities — Metropolitan Edison Company (“Met-Ed”), Pennsylvania Electric Company (“Penelec”), Pennsylvania Power Company (“Penn Power”) and West Penn Power Company (“West Penn Power”) — to procure full requirements Default Supply generation service for their Default Service Customers for the delivery period beginning June 2015. CRA International Inc. (NASDAQ:CRAI) ended the last trading day at $31.90. Company weekly volatility is calculated as 2.97% and price to cash ratio as 6.80. CRA International Inc. (NASDAQ:CRAI) showed a weekly performance of 0.19%. Furniture leaser Aaron's, Inc. (NYSE:AAN) announced Monday that John W. Robinson III has been appointed chief executive officer, effective immediately. Robinson will also be a member of the franchisor's board of directors. Aaron's, Inc. (NYSE:AAN) shares decreased -0.33% in last trading session and ended the day at $27.51. AAN Gross Margin is 85.90% and its return on assets is 3.80%. Aaron's, Inc. (NYSE:AAN) quarterly performance is 6.22%.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.